CTN-0097: Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder

Adam Bisaga, MD
Lead Investigator

New York State Psychiatric Institute
Division on Substance Abuse
adam.bisaga@nyspi.columbia.edu

Edward V. Nunes, Jr., MD
Lead Investigator

Columbia University College of Physicians and Surgeons and New York State Psychiatric Institute
nunesed@pi.cpmc.columbia.edu

Inpatient programs are important portals for increasing access to treatment. However, most individuals with opioid use disorder are detoxified but not offered medications to prevent relapse. This randomized-controlled trial will examine whether a rapid-transition protocol to inducting extended release naltrexone (XR-NTX) following detoxification yields a higher proportion of patients successfully receiving the first injection of XR-NTX compared to standard detoxification and naltrexone initiation. This study will also assess facilitators and barriers to implementing rapid XR-NTX initiation. The overall goal is to foster widespread adoption of a 5-7-day protocol for initiation of treatment with XR-NTX at Inpatient/Residential programs.

Funded by the NIH HEAL InitiativeSM.

    Node Involvement

    Lead Node(s):

  • New York Node

  • All Participating Nodes:

  • Florida Node Alliance
  • New York Node